MONTIGET 4 MG GRANULES SACHET
Description : Montelukast sodium is a selective and orally active leukotriene receptor antagonist that inhibits the cysteinyl leukotriene CysLT1 receptor, stimulation of which by circulating leukotrienes is thought to play a role in the pathogenesis of asthma. It supresses both early and late bronchoconstrictor responses to inhaled antigens or irritations, but is not suitable for the management of acute attacks of asthma.
Montelukast sodium is [R-(E)]-1-[[[1-[3-[2-(7-chloro-2 quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid, monosodium salt. The molecular formula is C35H35CINNaO3S.
Indications / Uses : Prophylaxis and chronic treatment of asthma including prevention of day and night time symptoms, treatment of aspirin-sensitive asthmatic patients and prevention of exercise-induced bronchoconstriction.
Relief of symptoms of seasonal allergic rhinitis in adults and pediatric patients =2 years.
Administration : May be taken with or without food.
Contraindications : Patients who has shown hypersensitivity to montelukast sodium or any of its components.
Montelukast sodium is not indicated for use in acute asthma attacks including status asthmaticus.
Special Precautions : General: Montelukast sodium should not be abruptly substituted for inhaled or oral corticosteroids. However, the dose of inhaled corticosteroid may be reduced gradually under medical supervision.
Although a casual relationship with leukotriene receptor antagonism has not been established, caution and appropriate clinical monitoring is recommended when systemic corticosteroid reduction is considered in patients receiving montelukast sodium.
Montelukast sodium should not be used as monotherapy for the treatment and management of exercise-induced asthma. Patients who have exacerbations of asthma after exercise should continue to use their usual regimen of inhaled ?-agonists as prophylaxis and should have it available as and when required.
Montelukast sodium does not block bronchoconstrictor response to aspirin or NSAIDs in aspirin-sensitive asthmatic patients. Such patients should continue to avoid aspirin and other NSAIDs.
Caution should be exercised when using montelukast sodium with bronchodilator therapy. When clinical response is apparent, the bronchodilator therapy should be reduced.
Use in pregnancy: Montelukast sodium has not been studied in pregnant women. It should be used during pregnancy only if clearly needed.
Use in lactation: It is not known if montelukast sodium is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when montelukast sodium is given to a nursing mother.